SynthesisInternational ophthalmology2025
The safety and efficacy of intra-canalicular dexamethasone insert for ocular pain and inflammation management post-cataract surgery: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cataract surgery is often associated with postoperative inflammation and pain, which, if inadequately managed, can lead to complications such as macular edema, increased intraocular pressure, and delayed recovery. Topical corticosteroids are the standard treatment but are limited by poor patient adherence and administration challenges. The intracanalicular dexamethasone insert (DEXTENZA) offers a sustained, automated drug delivery platform that addresses these limitations. This systematic review and meta-analysis evaluated the efficacy and safety of DEXTENZA for managing postoperative pain and inflammation following cataract surgery. A comprehensive search of PubMed, Embase, Cochrane Library, Directory of Open Access Journals (DOAJ), and ClinicalTrials.gov-without date restrictions-identified four randomized controlled trials (RCTs) involving 985 participants The protocol was registered with PROSPERO (CRD42023457981). This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Meta-analysis demonstrated that DEXTENZA significantly reduced anterior chamber cell clearance (RR = 1.63, 95% CI = 1.27-2.08, P = 0.0001) by day 14 and improved pain resolution (RR = 1.59, 95% CI = 1.24-2.03, P = 0.0002) by day 8 compared to placebo. Adverse events, including non-serious and serious ocular incidents, were lower in the DEXTENZA group (RR = 0.57, 95% CI = 0.42-0.78, P = 0.0005). The sustained-release mechanism of DEXTENZA improves adherence and may offer practical advantages in postoperative management, particularly in patients with challenges using topical drops these findings support the use of intracanalicular corticosteroids as a promising alternative for managing postoperative pain and inflammation in cataract surgery patients.
Indexed as
Identifiers
40493316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.